FDA Approves Subcutaneous Rybrevant Faspro for EGFR-Mutated Non-Small Cell Lung Cancer

TUESDAY, Dec. 23, 2025-- The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth factor receptor...